Antibiotics Market Expansion Driven by Rising Surgical Procedures Globally

1. Antibiotics Market Expansion Driven by Rising Surgical Procedures Globally The antibiotics market plays a critical role in global healthcare by treating a wide range of bacterial infections. This market includes drug classes such as penicillins, cephalosporins, macrolides, and fluoroquinolones, which are used in hospitals, clinics, and outpatient care settings. Growth is driven by the rising incidence of infectious diseases, increasing awareness about early treatment, and advancements in drug formulations. Efforts to combat antibiotic resistance and the development of novel antibiotics are also shaping the market’s future. As healthcare access expands, particularly in emerging economies, the demand for effective and affordable antibiotics continues to rise. According to Fortune Business Insights, the global antibiotics market was valued at USD 41.63 billion in 2024. The market is projected to grow from USD 43.17 billion in 2025 to USD 58.24 billion by 2032, exhibiting a CAGR of 4.4% during the forecast period. In 2024, North America dominated the antibiotics market with a market share of 45.14%. Top Companies Steering the Market           Pfizer Inc. (U.S.) Abbott (U.S.) GSK plc. (U.K.) Sandoz Group AG (Switzerland) Bayer AG (Germany) Bristol-Myers Squibb Company (U.S.) Merck & Co., Inc. (U.S.) Astellas Pharma Inc. (Japan) Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.) (U.S.) AbbVie Inc. (U.S.) Key Industry Development – October 2024 In October 2024, Iterum Therapeutics plc of Ireland received FDA approval for ORLYNVAH (sulopenem etzadroxil with probenecid) to treat uncomplicated urinary tract infections (uUTIs). This new antibiotic combination addresses the growing need for effective therapies amid rising resistance . Market Drivers & Growth Catalysts ? ? Rising Prevalence of Bacterial Infections The alarming surge in bacterial infections—ranging from tuberculosis and respiratory infections to skin and urinary tract infections—is a primary growth driver. Notably, the World Health Organization reported 10.8 million TB cases in 2023, underscoring global demand for antibiotics . Healthcare-associated infections (HAIs) also elevate antibiotic use, with one in ten patients affected in low- or middle-income countries . ? ? Increased Antibiotic Consumption

2. A recent PNAS study spanning 63 countries revealed antibiotic consumption grew from 29.5 billion to 34.3 billion Defined Daily Doses (DDDs) from 2016 to 2023—a 16.3% surge . Sustained use and prescription volume continue to underpin market expansion. ? ? Focus on Novel Combination Therapies New FDA-approved combinations like EMBLAVEO (aztreonam + avibactam) by AbbVie in February 2025 target drug-resistant infections such as complicated intra-abdominal infections, illustrating significant R&D investment in combating antimicrobial resistance . Market Restraints & Challenges ⚠️ ⚠️ Escalating Antimicrobial Resistance (AMR) Overuse of antibiotics has accelerated the rise of antimicrobial resistance. In 2021 alone, AMR contributed to 1.14 million direct deaths and 4.71 million total deaths—a trend that may reach 10 million annually by 2050 . Such resistance has intensified scrutiny of antibiotic usage and reduced prescribing trends. ? ? Mounting Global Healthcare Costs AMR-related health expenses could soar by USD 1 trillion by 2050, alongside GDP losses of up to USD 3.4 trillion —altering the economic landscape and placing new constraints on antibiotic pricing and usage. ? ? Decline in Prescription Rates

3. Efforts to promote antibiotic stewardship are yielding results: a 2022 U.S. Ambulatory Safety Program reduced prescriptions overall by 48% and respiratory-infection prescriptions by 37% . While combatting AMR, these initiative-driven reductions limit market expansion. Emerging Trends & Market Opportunities ? ? Antimicrobial Stewardship Programs (ASPs) Global efforts like Zambia and Kenya’s ASPIRE initiative focus on stewardship and policy reforms using digital tools—aiming to optimize antibiotic usage and slow resistance . ? ? Innovation in Drug Classes Penicillins continue to dominate, thanks to high usage and generic releases, while newer cephalosporins (e.g., ZEVTERA by Basilea, FDA-approved April 2024) broaden clinical options . Additionally, fluoroquinolones are recuperating with generic entries like levofloxacin oral solution . ? ? Oral vs. Parenteral Preference Parenteral antibiotics—including high-profile injectables like Fetroja (cefiderocol)—lead market share due to their crucial role in treating severe infections (sepsis, pneumonia) . Oral medications like Blujepa (gepotidacin) offer convenience for outpatient care . ? ? Rise of Online Pharmacies Online antibiotic sales are gaining traction, driven by telemedicine and e-prescriptions—while hospital and retail pharmacies continue to anchor distribution with widespread availability . Market Segmentation Overview By Drug Class:     Penicillins: Largest class in 2024, driven by generic accessibility . Cephalosporins: Fastest-growing, driven by multi-generation launches like ZEVTERA . Fluoroquinolones: Seeing growth via generics like levofloxacin. Macrolides, tetracyclines, aminoglycosides, sulfonamides, and others. By Application:  Respiratory Infections: Dominant application—pneumonia infects 1,400+ per 100,000 children globally. UTIs: Second-largest, fueled by approvals like EXBLIFEP. Also includes skin, ear, GI infections, septicemia.   By Route of Administration:   Parenteral: Leading route due to severe infection treatment, injectables like Fetroja. Oral: Convenient for outpatient regimens; Blujepa’s approval demonstrates ongoing expansion.

4.  Others: Inhaled, topical, rectal formats. By Distribution Channel:    Hospital Pharmacies: Primary distribution point for serious infectious treatments. Retail Pharmacies: Widely accessible for outpatient antibiotic use. Online Pharmacies: Fast-growing segment, fueled by telehealth trends. Regional Insights & Outlook North America In 2024, this region led with USD 18.79 billion (45% of market share), supported by advanced healthcare infrastructure and strong R&D investments . The U.S. alone sees 756 antibiotic prescriptions per 1,000 residents. Europe Europe holds the second-largest share, driven by mature healthcare systems and generic drug pipelines. Notable approvals like Pivya (pivmecillinam) reinforce market strength. Asia-Pacific Fastest-growing region—driven by high generic antibiotic usage and new drug approvals such as Plazomicin in India. Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/antibiotics-market-104583 Future Market Scope The antibiotics market is unmistakably evolving toward advanced combination therapies, stewardship- backed prescribing, and digital delivery platforms. Expected growth will be powered by:    Continuous development of novel drug classes and generics Expansion of stewardship programs to balance use and resistance Greater online pharmacy penetration paired with remote healthcare access All the while, AMR continues to shape market dynamics—propelling innovation while curbing indiscriminate usage. The battle against resistance will define how antibiotics retain their efficacy and market significance into 2032 and beyond. About Us: Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in. Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.

5. At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges. Contact us: Fortune Business Insights™ Pvt. Phone: USA: +1 833 909 2966 (Toll-Free), United Kingdom: +44 808 502 0280 (Toll-Free), APAC: +91 744 740 1245 Email: sales@fortunebusinessinsights.com